Adjuvant Chemotherapy for Colorectal Cancer

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2002 Sep 14

PMID 12228045

Citations 4

Authors

Anne Demols

Jean-Luc Van Laethem

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is the second leading cause of cancer death in Western countries. If surgery remains the only cure, recurrence rates for colon cancer range from 30% to 60% for stage III tumors. Adjuvant chemotherapy is the standard treatment for stage III colon tumors and consists of monthly administration of bolus 5-fluorouracil and leucovorin for 5 consecutive days a month over a 6-month period (Mayo regimen). Adjuvant chemotherapy for stage II colon cancer remains controversial, and its administration is not routinely recommended except in certain high-risk and selected patients. Immunotherapy, new drug-based therapies or combinations, and cyclooxygenase-2 inhibitors are being tested in the adjuvant setting. Total mesorectum excision is now the gold standard surgical technique for rectal cancer resection, and this procedure has dramatically decreased local recurrence. Nevertheless, adjuvant chemoradiotherapy is commonly indicated in the United States. In Europe, neoadjuvant radiotherapy is recommended for stage II and III resectable rectal cancers; the role of chemotherapy remains mostly investigational.

Citing Articles

A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Duggan M, Jochems C, Donahue R, Richards J, Karpa V, Foust E Cancer Immunol Immunother. 2016; 65(11):1353-1364.

PMID: 27581603 PMC: 5071149. DOI: 10.1007/s00262-016-1893-7.

Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.

Stella Tsai C, Chen H, Tung J, Tsou S, Tsao T, Liao C Am J Pathol. 2010; 176(4):1619-28.

PMID: 20150437 PMC: 2843454. DOI: 10.2353/ajpath.2010.090467.

T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody.

Mosolits S, Markovic K, Fagerberg J, Frodin J, Rezvany M, Kiaii S Cancer Immunol Immunother. 2004; 54(6):557-70.

PMID: 15570423 PMC: 11034216. DOI: 10.1007/s00262-004-0620-y.

Tumor micrometastases in mesorectal lymph nodes and their clinical significance in patients with rectal caner.

Zheng Y, Tang Y, Zhou Z, Li L, Wang T, Deng Y World J Gastroenterol. 2004; 10(22):3369-73.

PMID: 15484321 PMC: 4572316. DOI: 10.3748/wjg.v10.i22.3369.

References

Hanna Jr M, Hoover Jr H, Vermorken J, Harris J, Pinedo H . Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001; 19(17-19):2576-82. DOI: 10.1016/s0264-410x(00)00485-0. View

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001; 19(21):4097-106. DOI: 10.1200/JCO.2001.19.21.4097. View

Cedermark B, Dahlberg M, Glimelius B, Pahlman L, Rutqvist L, Wilking N . Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997; 336(14):980-7. DOI: 10.1056/NEJM199704033361402. View

Kapiteijn E, Marijnen C, Nagtegaal I, Putter H, Steup W, Wiggers T . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345(9):638-46. DOI: 10.1056/NEJMoa010580. View

Lenz H, Danenberg K, Leichman C, Florentine B, Johnston P, Groshen S . p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res. 1998; 4(5):1227-34. View

Mamounas E, Wieand S, Wolmark N, Bear H, Atkins J, Song K . Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999; 17(5):1349-55. DOI: 10.1200/JCO.1999.17.5.1349. View

Salonga D, Danenberg K, Johnson M, Metzger R, Groshen S, Tsao-Wei D . Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000; 6(4):1322-7. View

Heald R, Husband E, Ryall R . The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?. Br J Surg. 1982; 69(10):613-6. DOI: 10.1002/bjs.1800691019. View

Francini G, Petrioli R, Lorenzini L, Mancini S, ARMENIO S, Tanzini G . Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology. 1994; 106(4):899-906. DOI: 10.1016/0016-5085(94)90748-x. View

10.

Reddy B, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S . Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000; 60(2):293-7. View

11.

Midgley R, Kerr D . Colorectal cancer. Lancet. 1999; 353(9150):391-9. DOI: 10.1016/S0140-6736(98)07127-X. View

12.

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Tangen C . Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995; 13(12):2936-43. DOI: 10.1200/JCO.1995.13.12.2936. View

13.

Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D . Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst. 1998; 90(23):1810-6. DOI: 10.1093/jnci/90.23.1810. View

14.

Vaillant J, Nordlinger B, Deuffic S, Arnaud J, Pelissier E, Favre J . Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. Ann Surg. 2000; 231(4):449-56. PMC: 1421018. DOI: 10.1097/00000658-200004000-00001. View

15.

. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet. 2000; 355(9215):1588-96. View

16.

Taketo M . COX-2 and colon cancer. Inflamm Res. 1998; 47 Suppl 2:S112-6. DOI: 10.1007/s000110050295. View

17.

Popescu R, Norman A, Ross P, Parikh B, Cunningham D . Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999; 17(8):2412-8. DOI: 10.1200/JCO.1999.17.8.2412. View

18.

Giovannucci E, Rimm E, Stampfer M, Colditz G, Ascherio A, Willett W . Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994; 121(4):241-6. DOI: 10.7326/0003-4819-121-4-199408150-00001. View

19.

Sargent D, Goldberg R, JACOBSON S, Macdonald J, Labianca R, Haller D . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345(15):1091-7. DOI: 10.1056/NEJMoa010957. View

20.

Deans G, Parks T, Rowlands B, Spence R . Prognostic factors in colorectal cancer. Br J Surg. 1992; 79(7):608-13. DOI: 10.1002/bjs.1800790706. View